Verastem, Inc. entered an agreement with Laboratory Corp. of America Holdings to validate biomarkers for its lead focal adhesion kinase (FAK) inhibitor VS-6063 in the development of an applicable companion diagnostic. The biomarkers will be the subject of clinical studies in ovarian cancer and mesothelioma, including a potentially pivotal study of VS-6063 in mesothelioma expected to initiate later this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.36 USD | +12.75% | +22.63% | -58.72% |
Jul. 12 | Sector Update: Health Care Stocks Higher in Late Afternoon Trading | MT |
Jul. 12 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.72% | 85.09M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- VSTM Stock
- News Verastem, Inc.
- Verastem, Inc. Enters Biomarker Agreement with Laboratory Corp. of America Holdings for Cancer Stem Cell Agent Companion Diagnostic